immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+-BMS-986207 in patients with platinum resistant ovarian cancer

Gady Cojocaru¹, Zoya Alteber¹, Assaf Wool¹, Adi Shuchami¹, Inbal Barbiro¹, Roy Granit¹, Yu Liang², Zurit Levine³, Pierre Ferre¹ and Eran Ophir¹

¹Compugen Ltd., Holon, Israel
²Compugen USA Inc., South San Francisco, CA

Background

COM701 is a 1st in-class, T-cell checkpoint-inhibitor that binds to PVRIG, blocking its interaction with PVRL2 expressed on tumor and antigen-presenting cells. We have reported initial anti-tumor activity of COM701+nivolumab+-BMS-986207 (anti-TIGIT) in patients with platinum-resistant ovarian cancer (PROC) [1,2]. Checkpoint inhibitors have limited activity in PROC patients, particularly in patients with reduced PD-L1 and T cell infiltration [3]. Here, we present preliminary translational assessment of PROC patients treated with COM701+nivolumab+-BMS-986207.

Methods

Pretreatment (n=28) and on-treatment (n=21) biopsies were collected from patients treated with COM701+nivolumab+-BMS-986207 Q4W (NCT03667716 and NCT04570839) and subjected to IHC stain with anti-PD-L1, anti-CD8, anti-PVRL2 and anti-PVRIG. Selected biopsies were subjected to ImmunoID NeXT assay. Patient IHC data from both studies were pooled for analysis.

Results

Patients with PR or SD>180 days (per RECIST) were defined as having clinical benefit (CB) versus NCB patients (PD or SD<180).

Clinical responses were independent of PD-L1, CD8 and PVRIG baseline expression: 3/7 CB patients had baseline PD-L1 CPS<1; median CD8 and PVRIG pre-levels were similar for both CB and NCB patients (Figure1A). In contrast, higher baseline PVRL2 H-score was correlated with response with median PVRL2 score of 290 in CB versus 240 NCB patients (p=0.05, Figure 1B). Examining tumor structural genomic-variants (by exome-DNAseq) revealed one responding patient (PR) with a genomic PVRL2-amplification
and baseline PVRL2 H-score of 300 (figure2A). TCGA analysis revealed that ovarian and gastric-tumors have an amplification of PVRL2 rate of ~3-5% which is correlated with higher mRNA expression (Figure2B).

Investigating immune modulation, CD8 increase was shown in 8/13 patients with paired biopsies, with a prominent increase in CB patients and trend for stronger CD8 increase in patients treated with triple versus dual blockade (Figure3). Paired TCR sequencing of three CB patients demonstrated an increase in the number of TCRb clones, where the most dominant on-treatment clones were present pretreatment and expanded in the TME following treatment (Figure4). CD8 increase demonstrated by IHC and mRNA (deconvolution-score) in a patient with PR, was accompanied by an increase in T-cell clone numbers and clonality and increase in M1 macrophages, while M2 macrophages mRNA-signature decreased (Figure5).

**Conclusions**

These results demonstrate the efficacy of COM701 treatment combinations in terms of clinical responses and immune modulation, regardless of the tumor baseline inflammatory status. In addition, the preliminary correlation between the expression of the PVRIG ligand, PVRL2, and clinical benefit may suggest the potential of baseline PVRL2 as a biomarker to enrich for responding patients.

**References:**

1. Abstract #159P; ESMO-IO 2022

2. Abstract #158P; ESMO-IO; 2022

Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+-BMS-986207 in patients with platinum resistant ovarian carcinoma

COM701 Translational Abstract
Figure 1: PVRL2 baseline levels correlate with clinical benefit (CB) in PROC patients treated with COM701+nivolumab or COM701+BMS-986207+nivolumab.
Figure 2: PVRL2 genomic amplification observed in a patient with durable partial response following COM701+BMS-986207+nivolumab treatment

A

Potential saturated PVRL2 signal in pre-treatment biopsy

B

PVRL2 genomic amplification (19q13) observed in OvCa and STAD - TCGA data
Figure 3: Increased CD8 infiltration following dual and triple blockade

%CD8 change on treatment

- Baseline
  - triplet
  - doublet
- On

Mean difference:
- Pts with CB: 2.66
- Pts with NCB: 1.16

Confidential
Figure 4: TME Increase in TCR clones following dual and triple blockade in CB patients
**Figure 5: Potent immune stimulation in a patient with PR following COM701+BMS-986207+nivolumab treatment**

<table>
<thead>
<tr>
<th></th>
<th>Pre</th>
<th>On</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD8</td>
<td>$0.45 \times 10^{-4} \text{CD8}/\mu\text{m}^2$</td>
<td>$6.72 \times 10^{-4} \text{CD8}/\mu\text{m}^2$</td>
</tr>
</tbody>
</table>

**Diagram B**

- **CD8**
- **IFNg signature**
- **TCRb clone number**
- **Gini Coefficient**
- **M1 Macrophages**
- **M2 Macrophages**